Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 2005 Feb;60(2):144–152. doi: 10.1136/thx.2004.025692

Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells

M Mata 1, B Sarria 1, A Buenestado 1, J Cortijo 1, M Cerda 1, E Morcillo 1
PMCID: PMC1747298  PMID: 15681504

Abstract

Background: A common pathological feature of chronic inflammatory airway diseases such as asthma and chronic obstructive pulmonary disease (COPD) is mucus hypersecretion. MUC5AC is the predominant mucin gene expressed in healthy airways and is increased in asthmatic and COPD patients. Recent clinical trials indicate that phosphodiesterase type 4 (PDE4) inhibitors may have therapeutic value for COPD and asthma. However, their direct effects on mucin expression have been scarcely investigated.

Methods: MUC5AC mRNA and protein expression were examined in cultured human airway epithelial cells (A549) and in human isolated bronchial tissue stimulated with epidermal growth factor (EGF; 25 ng/ml). MUC5AC mRNA was measured by real time RT-PCR and MUC5AC protein by ELISA (cell lysates and tissue homogenates), Western blotting (tissue homogenates) and immunohistochemistry.

Results: EGF increased MUC5AC mRNA and protein expression in A549 cells. PDE4 inhibitors produced a concentration dependent inhibition of the EGF induced MUC5AC mRNA and protein expression with potency values (–log IC50): roflumilast (∼7.5) > rolipram (∼6.5) > cilomilast (∼5.5). Roflumilast also inhibited the EGF induced expression of phosphotyrosine proteins, EGF receptor, and phospho-p38- and p44/42-MAPK measured by Western blot analysis in A549 cells. In human isolated bronchus, EGF induced MUC5AC mRNA and protein expression was inhibited by roflumilast (1 µM) as well as the MUC5AC positive staining shown by immunohistochemistry.

Conclusion: Selective PDE4 inhibition is effective in decreasing EGF induced MUC5AC expression in human airway epithelial cells. This effect may contribute to the clinical efficacy of this new drug category in mucus hypersecretory diseases.

Full Text

The Full Text of this article is available as a PDF (336.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baillie G. S., MacKenzie S. J., McPhee I., Houslay M. D. Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. Br J Pharmacol. 2000 Oct;131(4):811–819. doi: 10.1038/sj.bjp.0703636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Basbaum Carol, Li Daizong, Gensch Erin, Gallup Marianne, Lemjabbar Hassan. Mechanisms by which gram-positive bacteria and tobacco smoke stimulate mucin induction through the epidermal growth factor receptor (EGFR). Novartis Found Symp. 2002;248:171-6; discussion 176-80, 277-82. [PubMed] [Google Scholar]
  3. Berger J. T., Voynow J. A., Peters K. W., Rose M. C. Respiratory carcinoma cell lines. MUC genes and glycoconjugates. Am J Respir Cell Mol Biol. 1999 Mar;20(3):500–510. doi: 10.1165/ajrcmb.20.3.3383. [DOI] [PubMed] [Google Scholar]
  4. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  5. Chijiwa T., Mishima A., Hagiwara M., Sano M., Hayashi K., Inoue T., Naito K., Toshioka T., Hidaka H. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem. 1990 Mar 25;265(9):5267–5272. [PubMed] [Google Scholar]
  6. Cortijo J., Villagrasa V., Pons R., Berto L., Martí-Cabrera M., Martinez-Losa M., Domenech T., Beleta J., Morcillo E. J. Bronchodilator and anti-inflammatory activities of glaucine: In vitro studies in human airway smooth muscle and polymorphonuclear leukocytes. Br J Pharmacol. 1999 Aug;127(7):1641–1651. doi: 10.1038/sj.bjp.0702702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Crump C. M., Williams J. L., Stephens D. J., Banting G. Inhibition of the interaction between tyrosine-based motifs and the medium chain subunit of the AP-2 adaptor complex by specific tyrphostins. J Biol Chem. 1998 Oct 23;273(43):28073–28077. doi: 10.1074/jbc.273.43.28073. [DOI] [PubMed] [Google Scholar]
  8. Dent G., White S. R., Tenor H., Bodtke K., Schudt C., Leff A. R., Magnussen H., Rabe K. F. Cyclic nucleotide phosphodiesterase in human bronchial epithelial cells: characterization of isoenzymes and functional effects of PDE inhibitors. Pulm Pharmacol Ther. 1998 Feb;11(1):47–56. doi: 10.1006/pupt.1998.0115. [DOI] [PubMed] [Google Scholar]
  9. Fuhrmann M., Jahn H. U., Seybold J., Neurohr C., Barnes P. J., Hippenstiel S., Kraemer H. J., Suttorp N. Identification and function of cyclic nucleotide phosphodiesterase isoenzymes in airway epithelial cells. Am J Respir Cell Mol Biol. 1999 Feb;20(2):292–302. doi: 10.1165/ajrcmb.20.2.3140. [DOI] [PubMed] [Google Scholar]
  10. Gensch Erin, Gallup Marianne, Sucher Anatol, Li Daizong, Gebremichael Assefa, Lemjabbar Hassan, Mengistab Aklilu, Dasari Vijay, Hotchkiss Jon, Harkema Jack. Tobacco smoke control of mucin production in lung cells requires oxygen radicals AP-1 and JNK. J Biol Chem. 2004 Jul 15;279(37):39085–39093. doi: 10.1074/jbc.M406866200. [DOI] [PubMed] [Google Scholar]
  11. Giembycz M. A. Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch Chest Dis. 2002 Feb;57(1):48–64. [PubMed] [Google Scholar]
  12. Groneberg D. A., Eynott P. R., Lim S., Oates T., Wu R., Carlstedt I., Roberts P., McCann B., Nicholson A. G., Harrison B. D. Expression of respiratory mucins in fatal status asthmaticus and mild asthma. Histopathology. 2002 Apr;40(4):367–373. doi: 10.1046/j.1365-2559.2002.01378.x. [DOI] [PubMed] [Google Scholar]
  13. Hatzelmann A., Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther. 2001 Apr;297(1):267–279. [PubMed] [Google Scholar]
  14. Hauck C. R., Sieg D. J., Hsia D. A., Loftus J. C., Gaarde W. A., Monia B. P., Schlaepfer D. D. Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells. Cancer Res. 2001 Oct 1;61(19):7079–7090. [PubMed] [Google Scholar]
  15. Kanehiro A., Ikemura T., Mäkelä M. J., Lahn M., Joetham A., Dakhama A., Gelfand E. W. Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge. Am J Respir Crit Care Med. 2001 Jan;163(1):173–184. doi: 10.1164/ajrccm.163.1.2001118. [DOI] [PubMed] [Google Scholar]
  16. Kawaguchi Mio, Kokubu Fumio, Matsukura Satoshi, Ieki Koushi, Odaka Miho, Watanabe Shin, Suzuki Shintaro, Adachi Mitsuru, Huang Shau-Ku. Induction of C-X-C chemokines, growth-related oncogene alpha expression, and epithelial cell-derived neutrophil-activating protein-78 by ML-1 (interleukin-17F) involves activation of Raf1-mitogen-activated protein kinase kinase-extracellular signal-regulated kinase 1/2 pathway. J Pharmacol Exp Ther. 2003 Oct 13;307(3):1213–1220. doi: 10.1124/jpet.103.056341. [DOI] [PubMed] [Google Scholar]
  17. Kirkham Sara, Sheehan John K., Knight David, Richardson Paul S., Thornton David J. Heterogeneity of airways mucus: variations in the amounts and glycoforms of the major oligomeric mucins MUC5AC and MUC5B. Biochem J. 2002 Feb 1;361(Pt 3):537–546. doi: 10.1042/0264-6021:3610537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kohri K., Ueki I. F., Shim J. J., Burgel P. R., Oh Y. M., Tam D. C., Dao-Pick T., Nadel J. A. Pseudomonas aeruginosa induces MUC5AC production via epidermal growth factor receptor. Eur Respir J. 2002 Nov;20(5):1263–1270. doi: 10.1183/09031936.02.00001402. [DOI] [PubMed] [Google Scholar]
  19. Labat C., Bara J., Gascard J. P., Sossé-Alaoui H., Thomas de Montpreville V., Yeadon M., Brink C. M1/MUC5AC mucin released by human airways in vitro. Eur Respir J. 1999 Aug;14(2):390–395. doi: 10.1034/j.1399-3003.1999.14b25.x. [DOI] [PubMed] [Google Scholar]
  20. Mata M., Ruíz A., Cerdá M., Martinez-Losa M., Cortijo J., Santangelo F., Serrano-Mollar A., Llombart-Bosch A., Morcillo E. J. Oral N-acetylcysteine reduces bleomycin-induced lung damage and mucin Muc5ac expression in rats. Eur Respir J. 2003 Dec;22(6):900–905. doi: 10.1183/09031936.03.00018003. [DOI] [PubMed] [Google Scholar]
  21. Pedrosa Rui, Gomes Pedro, Soares-da-Silva Patricío. Distinct signalling cascades downstream to Gsalpha coupled dopamine D1-like NHE3 inhibition in rat and opossum renal epithelial cells. Cell Physiol Biochem. 2004;14(1-2):91–100. doi: 10.1159/000076930. [DOI] [PubMed] [Google Scholar]
  22. Piiper A., Gebhardt R., Kronenberger B., Giannini C. D., Elez R., Zeuzem S. Pertussis toxin inhibits cholecystokinin- and epidermal growth factor-induced mitogen-activated protein kinase activation by disinhibition of the cAMP signaling pathway and inhibition of c-Raf-1. Mol Pharmacol. 2000 Sep;58(3):608–613. doi: 10.1124/mol.58.3.608. [DOI] [PubMed] [Google Scholar]
  23. Polosa Riccardo, Puddicombe Sarah M., Krishna M. Thirumala, Tuck Angela B., Howarth Peter H., Holgate Stephen T., Davies Donna E. Expression of c-erbB receptors and ligands in the bronchial epithelium of asthmatic subjects. J Allergy Clin Immunol. 2002 Jan;109(1):75–81. doi: 10.1067/mai.2002.120274. [DOI] [PubMed] [Google Scholar]
  24. Sandberg M., Butt E., Nolte C., Fischer L., Halbrügge M., Beltman J., Jahnsen T., Genieser H. G., Jastorff B., Walter U. Characterization of Sp-5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole- 3',5'-monophosphorothioate (Sp-5,6-DCl-cBiMPS) as a potent and specific activator of cyclic-AMP-dependent protein kinase in cell extracts and intact cells. Biochem J. 1991 Oct 15;279(Pt 2):521–527. doi: 10.1042/bj2790521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Sevetson B. R., Kong X., Lawrence J. C., Jr Increasing cAMP attenuates activation of mitogen-activated protein kinase. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10305–10309. doi: 10.1073/pnas.90.21.10305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Takeyama K., Dabbagh K., Jeong Shim J., Dao-Pick T., Ueki I. F., Nadel J. A. Oxidative stress causes mucin synthesis via transactivation of epidermal growth factor receptor: role of neutrophils. J Immunol. 2000 Feb 1;164(3):1546–1552. doi: 10.4049/jimmunol.164.3.1546. [DOI] [PubMed] [Google Scholar]
  27. Takeyama K., Dabbagh K., Lee H. M., Agustí C., Lausier J. A., Ueki I. F., Grattan K. M., Nadel J. A. Epidermal growth factor system regulates mucin production in airways. Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3081–3086. doi: 10.1073/pnas.96.6.3081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Takeyama K., Fahy J. V., Nadel J. A. Relationship of epidermal growth factor receptors to goblet cell production in human bronchi. Am J Respir Crit Care Med. 2001 Feb;163(2):511–516. doi: 10.1164/ajrccm.163.2.2001038. [DOI] [PubMed] [Google Scholar]
  29. Toward Toby J., Broadley Kenneth J. Goblet cell hyperplasia, airway function, and leukocyte infiltration after chronic lipopolysaccharide exposure in conscious Guinea pigs: effects of rolipram and dexamethasone. J Pharmacol Exp Ther. 2002 Aug;302(2):814–821. doi: 10.1124/jpet.102.033951. [DOI] [PubMed] [Google Scholar]
  30. Wetzker Reinhard, Böhmer Frank-D. Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat Rev Mol Cell Biol. 2003 Aug;4(8):651–657. doi: 10.1038/nrm1173. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES